Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GRN | P28799 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5525300 | 0.89 | HPGD (0.46) | HPGDCYP1A2SMN1; SMN2MAPK1POLB | |
| SCHEMBL5522868 | 0.83 | CYP19A1 (0.53) | HPGDSMN1; SMN2MAPK1POLBALDH1A1 | |
| SCHEMBL5531830 | 0.80 | MGLL (0.37) | HPGDCYP1A2SMN1; SMN2MAPK1POLB | |
| SCHEMBL5528723 | 0.79 | CCNA2 (0.42) | HPGDCYP1A2SMN1; SMN2MAPK1POLB | |
| SCHEMBL5079503 | 0.75 | CCNA2 (0.47) | HPGDSMN1; SMN2POLBCCNA2CDK2 | |
| SCHEMBL5525718 | 0.74 | CCNA2 (0.42) | HPGDCYP1A2SMN1; SMN2POLBCCNA2 | |
| SCHEMBL5526763 | 0.73 | TSHR (0.41) | HPGDPOLBKMT2AALDH1A1LMNA | |
| SCHEMBL14597506 | 0.72 | HPGD (0.42) | HPGDCYP1A2SMN1; SMN2MAPK1POLB | |
| SCHEMBL31706984 | 0.71 | HTR7 (0.58) | CCNA2CDK2CCNA1 | |
| SCHEMBL3775553 | 0.71 | PTGER4 (0.60) | HPGDCYP1A2SMN1; SMN2MAPK1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637555-B2 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20070072924-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20060217562-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | disclosed |
| EP-1683794-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | Arena Pharmaceuticals, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1599469-B1 | TETRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARM INC (US) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072924-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | SQLE, ACE, AGTR2 | HPGD 805/4885CYP1A2 219/4885SMN1; SMN2 4195/4885 |
| US-20060217562-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | SQLE, ACE, AGTR2 | HPGD 805/4885CYP1A2 219/4885SMN1; SMN2 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.